Thyroxine promotes lung cancer growth in an orthotopic mouse model
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Thyroid hormones are important for physiology and homeostasis. In addition to nuclear thyroid hormone receptors, the plasma membrane protein integrin α v β 3 has been recognized as a receptor for both thyroxine (T 4 ) and triiodothyronine (T 3 ). Here, we studied whether thyroid hormone promotes growth of murine lung cancer via α v β 3 in vivo . Murine Lewis lung carcinoma cells (3LL), stably transfected with luciferase, were injected into mouse lungs. Tumor growth in untreated mice was compared to hypothyroid mice and hypothyroid mice treated with T 3 or T 4 with or without the α v β 3 inhibitor 3,5,3′,5′-tetraiodothyroacetic acid (Tetrac). Tumor progression was determined by serial in vivo imaging of bioluminescence emitted from the tumor. Tumor weight was recorded at the end of the experiment. Neoangiogenesis was determined by immunohistochemistry for CD31. Tumor growth was reduced in hypothyroidism and increased by T 4 treatment. Strikingly, only T 4 but not T 3 treatment promoted tumor growth. This T 4 effect was abrogated by the α v β 3 inhibitor Tetrac. Tumor weight and neoangiogenesis were also significantly increased only in T 4 -treated mice. The T 4 effect on tumor weight and neoangiogenesis was abolished by Tetrac. In vitro , T4 did not stimulate 3LL cell proliferation or signaling pathway activation. We conclude that T 4 promotes lung cancer growth in this orthotopic mouse model. The tumor-promoting effect is mediated via the plasma membrane integrin α v β 3 and increased neoangiogenesis rather than direct stimulation of 3LL cells. These data suggest that such effects of levothyroxine may need to be considered in cancer patients on T 4 substitution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, T4 stimulates growth of cancer cells and tumors independently of either TRα or TRβ through αvβ3, the type 4 noncanonical pathway (Supplementary Table S3) (30–32).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [32]
In the citing paper
“In addition, T4 stimulates growth of cancer cells and tumors independently of either TRα or TRβ through αvβ3, the type 4 noncanonical pathway (online suppl. Table 3) [30-32].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659
Bergh, J. J., Lin, H.-Y., Lansing, L., Mohamed, S. N., Davis, F. B., Mousa, S., & Davis, P. J. (2005) · Endocrinology · doi:10.1210/en.2005-0102 · Cited by 497
The human genome encodes 10 α-crystallin–related small heat shock proteins: HspB1–10
Kappé, G., Franck, E., Verschuure, P., Boelens, W. C., Leunissen, J. A. M., & de Jong, W. W. (2003) · Cell Stress & Chaperones · doi:10.1379/1466-1268(2003)8<53:thgecs>2.0.co;2 · Cited by 434
Piali, L., Hammel, P., Uherek, C., Bachmann, F., Gisler, R. H., Dunon, D., & Imhof, B. A. (1995) · The Journal of cell biology · doi:10.1083/jcb.130.2.451 · Cited by 376
Lin, H.-Y., Sun, M., Tang, H.-Y., Lin, C., Luidens, M. K., Mousa, S. A., Incerpi, S., Drusano, G. L., Davis, F. B., & Davis, P. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00305.2008 · Cited by 255
Wilder, R. L. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii96 · Cited by 232
Membrane Receptor for Thyroid Hormone: Physiologic and Pharmacologic Implications
Davis, P. J., Davis, F. B., Mousa, S. A., Luidens, M. K., & Lin, H.-Y. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100512 · Cited by 204
Effects of thyroid hormones on human breast cancer cell proliferation
Hall, L. C., Salazar, E. P., Kane, S. R., & Liu, N. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.12.008 · Cited by 171
Thyroid Hormone Signaling Pathways: Time for a More Precise Nomenclature
Flamant, F., Cheng, S.-Y., Hollenberg, A. N., Moeller, L. C., Samarut, J., Wondisford, F. E., Yen, P. M., & Refetoff, S. (2017) · Endocrinology · doi:10.1210/en.2017-00250 · Cited by 165
Self-citationPOHLENZ, J., MAQUEEM, A., CUA, K., WEISS, R. E., VAN SANDE, J., & REFETOFF, S. (1999) · Thyroid · doi:10.1089/thy.1999.9.1265 · Cited by 154
Lin, H.-Y., Tang, H.-Y., Keating, T., Wu, Y.-H., Shih, A., Hammond, D., Sun, M., Hercbergs, A., Davis, F. B., & Davis, P. J. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm239 · Cited by 128
Kim, H. I., Kim, M., Lee, S.-H., Park, S. Y., Kim, Y. N., Kim, H., Jeon, M. J., Kim, T. Y., Kim, S. W., Kim, W. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1375642 · Cited by 123
The Role of αv Integrins during Angiogenesis
Eliceiri, B. P., & Cheresh, D. A. (1998) · Molecular Medicine · doi:10.1007/bf03401768 · Cited by 119
Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo
Hönes, G. S., Rakov, H., Logan, J., Liao, X.-H., Werbenko, E., Pollard, A. S., Præstholm, S. M., Siersbæk, M. S., Rijntjes, E., Gassen, J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706801115 · Cited by 116
Self-citationMeng, R., Tang, H.-Y., Doering, J., London, D., Cao, J. H., Mousa, S. A., Luidens, M. K., Hercbergs, A. H., Davis, F. B., Davis, P. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027547 · Cited by 108
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
Illouz, F., Braun, D., Briet, C., Schweizer, U., & Rodien, P. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0198 · Cited by 95
Mousa, S. A., Bergh, J. J., Dier, E., Rebbaa, A., O’Connor, L. J., Yalcin, M., Aljada, A., Dyskin, E., Davis, F. B., Lin, H.-Y., et al. (2008) · Angiogenesis · doi:10.1007/s10456-007-9088-7 · Cited by 87
Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3
Sahni, A., & Francis, C. W. (2004) · Blood · doi:10.1182/blood-2004-04-1358 · Cited by 82
Tsui, K., Hsieh, W., Lin, M., Chang, P., & Juang, H. (2008) · The Prostate · doi:10.1002/pros.20725 · Cited by 74
Christoph, S., DeRyckere, D., Schlegel, J., Frazer, J. K., Batchelor, L. A., Trakhimets, A. Y., Sather, S., Hunter, D. M., Cummings, C. T., Liu, J., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0040 · Cited by 72
Self-citationCao, X., Kambe, F., Yamauchi, M., & Seo, H. (2009) · Biochemical Journal · doi:10.1042/bj20090643 · Cited by 65
Poczobutt, J. M., Gijón, M. A., Amin, J., Hanson, D., Li, H. Y., Walker, D., Weiser-Evans, M. C. M., Lu, X. J. D., Murphy, R. C., & Nemenoff, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079633 · Cited by 59
Davis, P. J., Lin, H., Sudha, T., Yalçın, M., Tang, H.-Y., Hercbergs, A. A., Leith, J. T., Luidens, M. K., Ashur‐Fabian, O., Incerpi, S., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s67393 · Cited by 50
Structure and Function of Thyroid Hormone Plasma Membrane Transporters
Schweizer, U., Johannes, J., Bayer, D., & Braun, D. (2014) · European Thyroid Journal · doi:10.1159/000367858 · Cited by 49
Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems.
Kumar, M. S., Chiang, T., & Deodhar, S. D. (1979) · PubMed · Cited by 41
Combined QM/MM Study of Thyroid and Steroid Hormone Analogue Interactions with Integrin
Freindorf, M., Furlani, T. R., Kong, J., Cody, V., Davis, F. B., & Davis, P. J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/959057 · Cited by 38
Niu, J. X., Zhang, W. J., Ye, L. Y., Wu, L. Q., Zhu, G. J., Yang, Z. H., Grau, G. E., & Lou, J. N. (2007) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e3280145c00 · Cited by 35
Efficacy of protocols for induction of chronic hyperthyroidism in male and female mice
Engels, K., Rakov, H., Zwanziger, D., Hönes, G. S., Rehders, M., Brix, K., Köhrle, J., Möller, L. C., & Führer, D. (2016) · Endocrine · doi:10.1007/s12020-016-1020-8 · Cited by 26
Self-citationIncreased survival and inhibition of mammary tumors in hypothyroid mice
Shoemaker, J. P., Bradley, R. L., & Hoffman, R. V. (1976) · Journal of Surgical Research · doi:10.1016/0022-4804(76)90151-7 · Cited by 24
Kinoshita, S., Sone, S., Yamashita, T., Tsubura, E., & Ogura, T. (1991) · PubMed · Cited by 20
Research works printed but not linked: 1
- 2003, Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF, Cell Stress & Chaperones, 8, 37, 10.1379/1466-1268(2003)8 · doi:10.1379/1466-1268(2003)8
Cited by
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
Self-citationKeyl, J., Keyl, P., Montavon, G., Hosch, R., Brehmer, A., Mochmann, L. H., Jurmeister, P. S., Dernbach, G., Kim, M., Koitka, S., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00891-1 · Cited by 98
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationNano-Strategies Targeting the Integrin αvβ3 Network for Cancer Therapy
Cheng, T.-M., Chang, W.-J., Chu, H.-Y., Luca, R. D., Pedersen, J. Z., Incerpi, S., Li, Z., Shih, Y.-J., Lin, H., Wang, K., et al. (2021) · Cells · doi:10.3390/cells10071684 · Cited by 72
The Essential Factors of Establishing Patient-derived Tumor Model
Chen, C., Wu, L., Huang, Y., Chen, X., Wang, H., & Teng, L. (2020) · Journal of Cancer · doi:10.7150/jca.51749 · Cited by 49
Metadata
- Authors
- Latteyer, S., Christoph, S., Theurer, S., Hönes, G. S., Schmid, K. W., Führer, D., & Moeller, L. C.
- Affiliations
- University of Duisburg-Essen (DE)
- Corresponding author
- Moeller, L C
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2019-06
- Volume
- 26
- Issue
- 6
- Pages
- 565-574
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2922920959
- Cited by
- 31
- References
- 32
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 11 · 2020: 7 · 2019: 2
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- University of Chicago
- Deutsche Forschungsgemeinschaft
- Universität Duisburg-Essen
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- thyroxine, lung cancer, integrin αvβ3, thyroid hormones, tumor growth, neoangiogenesis, Lewis lung carcinoma, hypothyroidism, triiodothyronine, tetraiodothyroacetic acid, levothyroxine, thyroid hormone receptor
- MeSH terms
- Animals, Hypothyroidism, Male, Mice, Inbred C57BL, Neovascularization, Pathologic, Thyroxine, Tumor Cells, Cultured, Apoptosis, Carcinoma, Lewis Lung, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.